A review of the known MTA-cooperative PRMT5 inhibitors

Protein arginine methyltransferase 5 (PRMT5) represents a novel epigenetic anti-tumour target with significant clinical potential, and has attracted considerable interest from the academic research community and the pharmaceutical industry.